Aseptic fill finish refers to accurate and sterile filling / sealing of drug products into packaging containers, such as vials, syringes, ampoules and cartridges. These aseptic conditions during fill finish operations are not only essential for ensuring end-user’s safety, but also maintaining pharmacological efficacy and product quality. It is worth noting that aseptic fill finish operations require skilled personnel, specialized automated equipment, cleanroom setup and continuous supervision to maintain the sterility and safety of the final drug product. However, given the high cost of specialized equipment and affiliated expertise required for such operations, it is difficult for a drug developer with limited finances and capacity constraints to meet the needs of their clientele. As a result, various stakeholders are outsourcing their fill finish related needs to contract service providers, in order to ensure the development of quality drug products. In fact, a number of companies are involved in offering biologics fill finish services and small molecule fill finish services. Additionally, there is a need for expanding the capacity to meet the anticipated demand for such operations. For this purpose, service providers have inked several agreements over the last few years. Driven by the consistent initiatives being undertaken by players in this domain, the aseptic fill finish services market is anticipated to grow at a steady pace, over the coming years.
Key Market Insights
The Aseptic Fill Finish Services Market by Type of Molecule (Small Molecules and Biologics), Type of Packaging Container Offered (Ampoules, Cartridges, Syringes and Vials), Type of Drug Product (Antibodies, Cell Therapies, Gene Therapies, Oligonucleotides, Recombinant Proteins, Vaccines and Other Products), Scale of Operation (Preclinical / Clinical and Commercial), Company Size (Large, Mid-sized and Small), Target Therapeutic Area (Autoimmune Disorders, Cardiovascular Disorders, Infectious Diseases Oncological Disorders, and Other Disorders) and Geographical Regions (North America, Europe, Asia Pacific, Middle East and North Africa and Latin America): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape and future opportunity for the aseptic fill finish service providers. The report answers many key questions related to this domain.
Growing Demand for Aseptic Fill Finish Services
Aseptic fill finish is a critical step in the production of drugs, as it involves the aseptic filling and packaging of therapeutic products into containers. In fact, even a minute error during the aseptic filling process can lead to microbial contamination, posing a considerable risk to the patient’s health. Therefore, aseptic fill finish operations need to be performed under controlled environmental conditions, in order to minimize the exposure of drug product to factors that could negatively impact its stability and efficacy. This, in turn, helps in extending the shelf life of a drug product. It is also worth mentioning that, in recent years, many players are carrying out fill finish operations using automated equipment, without any manual intervention. This practice is believed to enhance the production efficiency, minimize downtime, reduce waste production, as well as increase the overall productivity. ,
Need for Outsourcing Aseptic Fill Finish Operations
The growing demand for pharmaceutical and biopharmaceutical drug products has created a need for higher capacity for production of therapies and their corresponding aseptic fill finish operations. However, extensive capital investment and complex infrastructure is necessary for carrying out in-house filling of biologics and small molecules. In addition, mishandling of drug product during the fill finish process can lead to microbial contamination, which can subsequently result in the loss of drug product, production delays and most importantly, pose a risk to the patient’s health. These aforementioned challenges have prompted pharmaceutical drug developers to outsource their fill finish operations to service providers, which have the required aseptic facilities and specialized equipment to ensure the quality of end products.
Key Drivers of the Aseptic Fill Finish Services Market
At present, the rising demand for outsourcing of aseptic fill finish services is driven by multiple factors, such as growing pipeline of drug products, stringent regulatory requirements, in-house capacity constraints, technological advancements and increased awareness related to the benefits of aseptic fill finish services.
Current Market Landscape of Aseptic Fill finish Service Providers
The current market landscape features the presence of over 235 aseptic fill finish service providers, spread across the globe. Overall, the market seems to be well-fragmented, featuring the presence of large, mid-sized and small companies, which have the required expertise to offer aseptic fill finish services across different types of packaging containers. Additionally, various recent developments in this segment of the pharmaceutical industry indicate that service providers are actively upgrading their sterile pharmaceutical manufacturing capabilities and infrastructure to accommodate the current and anticipated demand for aseptic fill finish services.
Overall Size of the Aseptic Fill Finish Services Market
Driven by the growing pipeline of pharmaceutical and biopharmaceutical drug products, as well as the rising demand for contract services in this sector, the aseptic fill finish market is anticipated to grow at a compound annual growth rate (CAGR) of 7%, during the period 2023-2035. Specifically, in terms of type of packaging container, the highest share of the market is anticipated to be captured by vials and prefilled syringes. In addition, at present, a major proportion of the market is represented by players based in North America and Europe.
Key Players in the Aseptic Fill Finish Services Market
Examples of key players engaged in offering aseptic fill finish services for biologics and small molecules include (which have been captured in this report) Aenova, AbbVie Contract Manufacturing, APL, Asymchem, BioPharma Solutions, BioReliance, Boehringer Ingelheim BioXcellence, Catalent Biologics, Charles River Laboratories, CordenPharma, Delpharm, Fareva, Fresenius Kabi, Glaxo SmithKline, Hetero Drugs, Intas Pharmaceuticals, Lonza, Pierre Fabre, Patheon, Pfizer CentreOne, Plastikon Healthcare, PiSA Farmaceutica, Recipharm, Sharp Services, Wacker Biotech, Syngene, Takara Bio, WuXi Biologics, Siegfried and Wockhardt.
Scope of the Report
The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different segments.
The study also presents an in-depth analysis of various stakeholders engaged in this domain, highlighting their capabilities across different geographies. Following are some of the key focus areas and topics elaborated in this report:
- A summary of the key insights derived from our research, which offers a high-level view on the likely evolution of the aseptic fill finish service providers market in the short to mid-term, and long term.
- A general introduction to pharmaceuticals and contract manufacturing, which features a detailed discussion on the need for outsourcing within the pharmaceutical industry and key operations outsourced by biologic and small molecule drug developers, including fill finish. It also provides information on the key considerations for selecting a fill finish service provider, along with the advantages and risks posed by outsourcing fill finish operations.
- A detailed assessment of the overall landscape of aseptic fill finish service providers, along with information on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, type of molecule(s) (biologics and small molecules) and type of packaging container(s) offered (ready-to-use cartridges, ready-to-use syringes and ready-to-use vials).
- A review of the overall landscape of companies offering aseptic fill finish services for biologics, along with analyses on a number of relevant parameters, such as year of establishment, company size, location of headquarters, location of fill finish facilities, type of packaging container(s) used (ampoules, cartridges, syringes and vials), type of biologic(s) manufactured (antibody drug conjugates, antibodies, biosimilars, cell therapies, gene therapies, oligonucleotides, peptides / proteins, vaccines, viral products, and others), scale of operation (preclinical, clinical and commercial) and type of additional drug product-related service(s) offered (lyophilization, labeling, quality testing, storage and distribution services).
- A detailed assessment of the overall market landscape of the companies offering aseptic fill finish services for small molecules, along with analyses on a number of relevant parameters, such as year of establishment, company size, location of headquarters, location of fill finish facilities, type of filling service(s) offered (aseptic filling, terminal streilization and blow-filling-seal), type of finishing service(s) offered (inspection and labelling and packaging), type of packaging container(s) offered (ampoules, cartridges, syringes and vials), scale of operation (preclinical, clinical and commercial), type of dosage form(s) filled (solid, liquids, lyophilized products / powders and semi-solids), type of process(es) (automated and manual / semi-automated).
- Tabulated profiles of key players based in North America, Europe and Asia-Pacific. Each profile provides an overview of the company, along with information on its service portfolio, fill finish facilities, financial information (if available), recent developments and an informed future outlook.
- A detailed analysis of the various partnerships and collaborations established by stakeholders in this domain, since 2013. It includes a brief description of different agreement models (including service agreements, service alliances, product integration agreements, joint ventures and acquisitions) adopted by stakeholders in this domain. Further, it comprises of analysis based on year of partnership, type of partnership, scale of operation, type of molecule(s), type of service(s) offered, type of process(es) involved, and type of drug product(s) filled. It also highlights the most active players (in terms of number of partnerships) in the domain.
- A case study focused on use of robotic systems in fill finish operations. It provides a list of equipment used by fill finish service providers (wherever specified), highlighting the purpose of robotics in various manufacturing operations. It also includes a list of companies offering robots for use in the manufacturing processes which are carried in the pharmaceutical sector.
- A case study on use of ready-to-use packaging components in aseptic fill finish operations. The chapter also provides information related to the advantages and disadvantages of ready-to-use packaging components, along with a list of suppliers providing these components.
One of the key objectives of this report was to estimate the current market size and future opportunities in the aseptic fill finish services market, over the coming 12 years. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2023-2035. In order to provide a detailed future outlook, year-wise projections of the current and future opportunity have been further segmented on the basis of type of molecule (small molecules and biologics), type of packaging container offered (ampoules, cartridges, syringes and vials), type of drug product (antibodies, cell therapies, gene therapies, oligonucleotides, recombinant proteins, vaccines and other drug products), target therapeutic area (autoimmune disorders, oncological disorders, cardiovascular disorders, infectious diseases and other disorders), scale of operation (preclinical / clinical and commercial), company size (large, mid-sized and small) and geography, (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America). To account for uncertainties in the market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in this report are backed by our understanding of key data generated from both secondary and primary research. The perceptions presented in this study were also influenced by our discussions with senior stakeholders in the industry.
The report further features detailed transcripts of interviews held with the following industry and non-industry players:
- Gregor Kawaletz (Former Chief Commercial Officer, IDT Biologika)
- Matt Delaney (Former Vice President Business Development & Marketing, Cytovance Biologics)
- Purushottam Singnurkar (Vice President and Head of Formulation Development, Syngene International)
- Ales Sima (Head of Business Development, Oncomed Manufacturing)
- Amit Chandra (Former Technology Watch Manager, Yposkesi)
- Jos Vergeest (International Business Developer, HALIX)
All actual figures have been sourced and analyzed from publicly available forums and primary research discussions. It is important to highlight that, financial figures mentioned in this report are in USD, unless otherwise specified.
Frequently Asked Questions
Question 1: What is the aseptic fill finish?
Answer: Fill finish is the last step in the aseptic manufacturing process, where drug products are filled and packaged in various packaging containers, such as vials, syringes, ampoules and cartridges, under sterile conditions. Further, the process is carried out in a controlled cleanroom environment, which has low levels of particulate matter and microorganisms to prevent microbial contamination. It is worth mentioning that fill finish is a complex and highly regulated process, to ensure the safety and efficacy of these drug products, as any contamination could lead to serious health risks for patients.
Question 2: What are the requirements and considerations for aseptic fill finish operation?
Answer: Aseptic filling process requires close coordination and complex interactions between supporting personnel and key operational equipment, sterilized drug product, cleanroom and other supporting facilities, and ancillary materials.
Question 3: How many players are providing aseptic fill finish services?
Answer: Presently, more than 235 companies offer aseptic fill finish and other related services (such as aseptic filling, terminal sterilization and blow-fill-seal).
Question 4: What are the latest trends in aseptic fill finish services market?
Answer: Aseptic fill finish market is evolving to meet the growing demands of the pharmaceutical and biopharmaceutical industry. Advanced technologies, such as robotics and single-use systems are being adopted to improve the accuracy, efficiency and safety of aseptic fill finish procedures. In fact, single-use technology reduces the risk of cross-contamination and need for cleaning validation. Further, automated aseptic filling systems reduce the human interference and can meet various operational requirements, from loading of raw material to cleaning of the equipment. This, in turn, can improve the consistency and quality of the final product.
Question 5: What is the growth rate of aseptic fill finish services market?
Answer: The global aseptic fill finish services market is expected to grow at a CAGR of 7%, during the period 2023-2035.
Question 6: Which region captures the largest share of the aseptic fill finish services market?
Answer: Currently, Europe contributes to more than 35% share of the overall market. Further, Asia-Pacific is likely to grow at a relatively faster pace, during the forecast period.
Question 7: Which segment, in terms of type of molecule, currently accounts for the largest share of the aseptic fill finish services market?
Answer: The small molecules segment currently holds the largest share (68%) in the overall aseptic fill finish services market. This trend is unlikely to change during the forecast period.
Question 8: Which types of packaging containers are most widely used in the aseptic fill finish services market?
Answer: Presently, the vials (67%) account for the largest share in the global aseptic fill finish services market.
Question 9: What type of partnerships are taking place in the aseptic fill finish services market?
Answer: At present, service agreements represent the most preferred type of partnership model adopted by stakeholders in this domain. This is followed by acquisitions and service alliances.
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
Table of Contents
1. PREFACE
1.1. Chapter Overview
1.2. Key Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Contract Manufacturing
3.3. Commonly Outsourced Operations in Biopharmaceutical Industry
3.3.1. Aseptic Fill / Finish Operations
3.4. Basic Guidelines for Selecting a Fill / Finish Service Provider
3.5. Advantages of Outsourcing Fill / Finish Operations
3.6. Risks and Challenges Associated with Outsourcing Fill / Finish Operations
3.7. Concluding Remarks
4. ASEPTIC FILL / FINISH SERVICE PROVIDERS LANDSCAPE
4.1. Chapter Overview
4.2. Aseptic Fill / Finish: Service Providers Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Molecule(s)
4.2.5. Analysis by Type of Packaging Container(s) Offered
5. BIOLOGICS FILL / FINISH SERVICE PROVIDERS LANDSCAPE
5.1. Chapter Overview
5.2. Biologics Fill / Finish: Service Providers Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Location of Fill / Finish Facilities
5.2.5. Analysis by Type of Packaging Container(s) Offered
5.2.6. Analysis by Type of Drug Product(s) Involved
5.2.7. Analysis by Scale of Operation
5.2.8. Analysis by Additional Drug Product-related Services Offered
5.2.9. Information on Fill / Finish Capacity
6. SMALL MOLECULE FILL / FINISH SERVICE PROVIDERS LANDSCAPE
6.1. Chapter Overview
6.2. Small Molecule Fill / Finish: Service Providers Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Location of Fill / Finish Facilities
6.2.5. Analysis by Type of Filling Service(s) Offered
6.2.6. Analysis by Type of Finishing Service(s) Offered
6.2.7. Analysis by Type of Packaging Container(s) Offered
6.2.8. Analysis by Scale of Operation
6.2.9. Analysis by Type of Dosage Form(s) Filled
6.2.10. Analysis by Type of Process(es)
6.2.11. Information on Fill / Finish Capacity
7. COMPANY PROFILES: ASEPTIC FILL / FINISH SERVICE PROVIDERS IN NORTH AMERICA
7.1. Chapter Overview
7.2. Companies Offering Aseptic Fill / Finish Services for Biologics
7.2.1. AbbVie Contract Manufacturing
7.2.1.1. Company Snapshot
7.2.1.2. Financial Information
7.2.1.3. Service Portfolio
7.2.1.4. Fill / Finish Services Offered
7.2.1.5. Recent Developments and Future Outlook
7.2.2. BioPharma Solutions
7.2.2.1. Company Snapshot
7.2.2.2. Financial Information
7.2.2.3. Service Portfolio
7.2.2.4. Fill / Finish Services Offered
7.2.2.5. Recent Developments and Future Outlook
7.2.3. BioReliance
7.2.3.1. Company Snapshot
7.2.3.2. Financial Information
7.2.3.3. Service Portfolio
7.2.3.4. Fill / Finish Services Offered
7.2.3.5. Recent Developments and Future Outlook
7.2.4. Catalent Biologics
7.2.4.1. Company Snapshot
7.2.4.2. Financial Information
7.2.4.3. Service Portfolio
7.2.4.4. Fill / Finish Services Offered
7.2.4.5. Recent Developments and Future Outlook
7.2.5. Charles River Laboratories
7.2.5.1. Company Snapshot
7.2.5.2. Financial Information
7.2.5.3. Fill / Finish Services Offered
7.2.5.4. Recent Developments and Future Outlook
7.2.6. Patheon
7.2.6.1. Company Snapshot
7.2.6.2. Financial Information
7.2.6.3. Service Portfolio
7.2.6.4. Fill / Finish Services Offered
7.2.6.5. Recent Developments and Future Outlook
7.3. Companies Offering Aseptic Fill / Finish Services for Small Molecules
7.3.1.1. Pfizer CentreOne
7.3.1.2. Company Snapshot
7.3.1.3. Service Portfolio
7.3.1.4. Fill / Finish Services Offered
7.3.1.5. Recent Developments and Future Outlook
7.3.2. Plastikon Healthcare
7.3.2.1. Company Snapshot
7.3.2.2. Service Portfolio
7.3.2.3. Fill / Finish Services Offered
7.3.2.4. Recent Developments and Future Outlook
7.3.3. Sharp Services
7.3.3.1. Company Snapshot
7.3.3.2. Service Portfolio
7.3.3.3. Fill / Finish Services Offered
7.3.3.4. Recent Developments and Future Outlook
8. COMPANY PROFILES: ASEPTIC FILL / FINISH SERVICE PROVIDERS IN EUROPE
8.1. Company Overview
8.2. Companies Offering Aseptic Fill / Finish Services for Biologics
8.2.1. Boehringer Ingelheim BioXcellence
8.2.1.1. Company Snapshot
8.2.1.2. Financial Information
8.2.1.3. Service Portfolio
8.2.1.4. Fill / Finish Services Offered
8.2.1.5. Recent Developments and Future Outlook
8.2.2. Fareva
8.2.2.1. Company Snapshot
8.2.2.2. Fill / Finish Services Offered
8.2.2.3. Recent Developments and Future Outlook
8.2.3. GlaxoSmithKline
8.2.3.1. Company Snapshot
8.2.3.2. Financial Information
8.2.3.3. Fill / Finish Services Offered
8.2.3.4. Recent Developments and Future Outlook
8.2.4. Lonza
8.2.4.1. Company Snapshot
8.2.4.2. Financial Information
8.2.4.3. Service Portfolio
8.2.4.4. Fill / Finish Services Offered
8.2.4.5. Recent Developments and Future Outlook
8.2.5. Pierre Fabre
8.2.5.1. Company Snapshot
8.2.5.2. Financial Information
8.2.5.3. Service Portfolio
8.2.5.4. Fill / Finish Services Offered
8.2.5.5. Recent Developments and Future Outlook
8.2.6. Wacker Biotech
8.2.6.1. Company Snapshot
8.2.6.2. Financial Information
8.2.6.3. Service Portfolio
8.2.6. 4. Fill / Finish Services Offered
8.2.6.5. Recent Developments and Future Outlook
8.3. Companies Offering Aseptic Fill / Finish Services for Small Molecules
8.3.1. Aenova
8.3.1.1. Company Snapshot
8.3.1.2. Financial Information
8.3.1.3. Service Portfolio
8.3.1.4. Fill / Finish Services Offered
8.3.1.5. Recent Developments and Future Outlook
8.3.2. APL
8.3.2.1. Company Snapshot
8.3.2.2. Service Portfolio
8.3.2.3. Fill / Finish Services Offered
8.3.2.4. Recent Developments and Future Outlook
8.3.3 CordenPharma
8.3.3.1. Company Snapshot
8.3.3.2. Service Portfolio
8.3.3.3. Fill / Finish Services Offered
8.3.3.4. Recent Developments and Future Outlook
8.3.4. Delpharm
8.3.4.1. Company Snapshot
8.3.4.2. Service Portfolio
8.3.4.3. Fill / Finish Services Offered
8.3.4.4. Recent Developments and Future Outlook
8.3.5 PiSA Farmaceutica
8.3.5.1. Company Snapshot
8.3.5.2. Service Portfolio
8.3.5.3. Fill / Finish Services Offered
8.3.5.4. Recent Developments and Future Outlook
8.4 Companies Offering Aseptic Fill / Finish Services for Biologics and Small Molecules
8.4.1 Fresenius Kabi
8.4.1.1. Company Snapshot
8.4.1.2 Financial Information
8.4.1.3. Service Portfolio
8.4.1.4. Fill / Finish Services Offered
8.4.1.5. Recent Developments and Future Outlook
8.4.2 Recipharm
8.4.2.1. Company Snapshot
8.4.2.2. Financial Information
8.4.2.3. Service Portfolio
8.4.2.4. Fill / Finish Services Offered
8.4.2.5. Recent Developments and Future Outlook
9. COMPANY PROFILES: ASEPTIC FILL / FINISH SERVICE PROVIDERS IN ASIA-PACIFIC
9.1 Company Overview
9.2 Companies Offering Aseptic Fill / Finish Services for Biologics
9.2.1 Asymchem
9.2.1.1. Company Snapshot
9.2.1.2. Financial Information
9.2.1.3. Service Portfolio
9.2.1.4. Fill / Finish Services Offered
9.2.1.5. Recent Developments and Future Outlook
9.2.2. Samsung Biologics
9.2.2.1. Company Snapshot
9.2.2.2. Financial Information
9.2.2.3. Service Portfolio
9.2.2.4. Fill / Finish Services Offered
9.2.2.5. Recent Developments and Future Outlook
9.2.3. Syngene
9.2.3.1. Company Snapshot
9.2.3.2. Financial Information
9.2.3.3. Service Portfolio
9.2.3.4. Fill / Finish Services Offered
9.2.3.5. Recent Developments and Future Outlook
9.2.4. Takara Bio
9.2.4.1. Company Snapshot
9.2.4.2. Financial Information
9.2.4.3. Service Portfolio
9.2.4.4. Fill / Finish Services Offered
9.2.4.5. Recent Developments and Future Outlook
9.2.5. WuXi Biologics
9.2.5.1. Company Snapshot
9.2.5.2. Financial Information
9.2.5.3. Service Portfolio
9.2.5.4. Fill / Finish Services Offered
9.2.5.5. Recent Developments and Future Outlook
9.2.6. Hetero Drugs
9.2.6.1. Company Snapshot
9.2.6.2. Fill / Finish Services Offered
9.2.6.3. Recent Developments and Future Outlook
9.2.7. Intas Pharmaceuticals
9.2.7.1. Company Snapshot
9.2.7.2. Fill / Finish Services Offered
9.2.7.3. Recent Developments and Future Outlook
9.3. Companies Offering Aseptic Fill / Finish Services for Small Molecules
9.3.1. Siegfried
9.3.1.1. Company Snapshot
9.3.1.2. Financial Information
9.3.1.3. Service Portfolio
9.3.1.4. Fill / Finish Services Offered
9.3.1.5. Recent Developments and Future Outlook
9.3.2. Wockhardt
9.3.2.1. Company Snapshot
9.3.2.2. Financial Information
9.3.2.3. Service Portfolio
9.3.2.4. Fill / Finish Services Offered
9.3.2.5. Recent Developments and Future Outlook
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Aseptic Fill / Finish Service Providers: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Scale of Operation
10.3.4. Analysis by Type of Molecule(s) Involved
10.3.5. Analysis by Type of Service(s) Offered
10.3.6. Analysis by Type of Process(es) Involved
10.3.7. Analysis by Type of Drug Product(s) Involved
10.3.8. Most Active Players: Analysis by Number of Partnerships
10.3.9. Analysis by Geography
10.3.9.1. Intercontinental and Intracontinental Agreements
11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology
11.3. Overall Aseptic Fill / Finish Services Market, 2023-2035
11.3.1. Aseptic Fill / Finish Services Market: Analysis by Type of Molecule, 2023-2035
11.3.2. Aseptic Fill / Finish Services Market: Analysis by Type of Packaging Container Offered, 2023-2035
11.3.3. Aseptic Fill / Finish Services Market: Analysis by Type of Drug Product, 2023-2035
11.3.4. Aseptic Fill / Finish Services Market: Analysis by Target Therapeutic Area, 2023-2035
11.3.5. Aseptic Fill / Finish Services Market: Analysis by Scale of Operation, 2023-2035
11.3.6. Aseptic Fill / Finish Services Market: Analysis by Company Size, 2023-2035
11.3.7. Aseptic Fill / Finish Services Market: Analysis by Geography, 2023-2035
11.4. Aseptic Fill / Finish Services Market for Biologics, 2023-2035
11.4.1. Aseptic Fill / Finish Services Market for Biologics: Analysis by Type of Packaging Container Offered, 2023-2035
11.4.2. Aseptic Fill / Finish Services Market: Analysis by Type of Drug Product, 2023-2035
11.4.3. Aseptic Fill / Finish Services Market for Biologics: Analysis by Target Therapeutic Area, 2023-2035
11.4.4. Aseptic Fill / Finish Services Market for Biologics: Analysis by Scale of Operation, 2023-2035
11.4.5. Aseptic Fill / Finish Services Market for Biologics: Analysis by Company Size, 2023-2035
11.4.6. Aseptic Fill / Finish Services Market for Biologics: Analysis by Geography, 2023-2035
11.5. Aseptic Fill / Finish Services Market for Small Molecules, 2023-2035
11.5.1. Aseptic Fill / Finish Services Market for Small Molecules: Analysis by Type of Packaging Container Offered, 2023-2035
11.5.2. Aseptic Fill / Finish Services Market for Small Molecules: Analysis by Scale of Operation, 2023-2035
11.5.3. Aseptic Fill / Finish Services Market for Small Molecules: Analysis by Company Size, 2023-2035
11.5.4. Aseptic Fill / Finish Services Market for Small Molecules: Analysis by Geography, 2023-2035
12. CASE STUDY: ROBOTICS IN PHARMACEUTICAL PACKAGING
12.1. Chapter Overview
12.2. Role of Robotic Systems in Pharmaceutical Industry
12.3. Role of Robotic Systems in Fill / Finish Operation
12.3.1. Types of Robots Used in Pharmaceutical Operations
12.3.2. Advantages Associated with Robotic Systems
12.3.3. Disadvantages Associated with Robotic Systems
12.4.2. Key Considerations for Selecting a Robotic System
12.3. Contract Service Providers: List of Fill / Finish Equipment
12.5. Companies Providing Robots for Use in the Pharmaceutical Industry
12.6. Companies Providing Isolator based Aseptic Filling Systems
12.7. Concluding Remarks
13. CASE STUDY: READY-TO-USE PACKAGING COMPONENTS FOR ASEPTIC FILL / FINISH
13.1. Chapter Overview
13.2. Role of Ready-to-Use Packaging Components in Aseptic Fill / Finish Operations
13.2.1. Advantages of Ready-to-Use Packaging Components
13.2.2. Disadvantages of Ready-to-Use Packaging Components
13.3. Companies Providing Ready-to-Use Packaging Components
13.4. Concluding Remarks
14. CONCLUDING REMARKS
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. IDT Biologika
15.2.1. Company Snapshot
15.2.1. Interview Transcript: Gregor Kawaletz, Former Chief Commercial Officer
15.3. Cytovance Biologics
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Matt Delaney, Former Vice President of Business Development and Marketing
15.4. Syngene
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Purushottam Singnurkar, Vice President and Head of Formulation Development
15.5. oncomed manufacturing
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Ales Sima, Head of Business Development
15.6. Yposkesi
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Amit, Former Technology Watch Manager
15.7. HALIX
15.7.1. Company Snapshot
15.7.2. Interview Transcript: Jos Vergeest, International Business Developer
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
List Of Figures
Figure 2.1 Executive Summary: Market Landscape of Biologics Fill / Finish Service Providers
Figure 2.2 Executive Summary: Market Landscape of Small Molecules Fill / Finish Service Providers
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Types of Third-Party Service Providers
Figure 3.2 Commonly Outsourced Fill / Finish Operations
Figure 3.3 Steps Involved in Aseptic Fill / Finish Process
Figure 3.4 Blow-Fill-Seal Process
Figure 3.5 Key Considerations for Selecting a CMO Partner
Figure 3.6 Risks and Challenges Associated with Outsourcing Aseptic Fill / Finish Operations
Figure 4.1 Aseptic Fill / Finish Service Providers: Distribution by Year of Establishment
Figure 4.2 Aseptic Fill / Finish Service Providers: Distribution by Company Size
Figure 4.3 Aseptic Fill / Finish Service Providers: Distribution by Location of Headquarters
Figure 4.4 Aseptic Fill / Finish Service Providers: Distribution by Type of Molecule(s)
Figure 4.5 Aseptic Fill / Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Figure 5.1 Biologics Fill / Finish Service Providers: Distribution by Year of Establishment
Figure 5.2 Biologics Fill / Finish Service Providers: Distribution by Company Size
Figure 5.3 Biologics Fill / Finish Service Providers: Distribution by Location of Headquarters
Figure 5.4 Biologics Fill / Finish Service Providers: Distribution by Location of Fill / Finish Facilities
Figure 5.5 Biologics Fill / Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Figure 5.6 Biologics Fill / Finish Service Providers: Distribution by Type of Packaging Container(s) Offered and Type of Drug Product(s) Involved
Figure 5.7 Biologics Fill / Finish Service Providers: Distribution by Scale of Operation
Figure 5.8 Biologics Fill / Finish Service Providers: Distribution by Additional Drug Product-related Services Offered
Figure 6.1 Small Molecules Fill / Finish Service Providers: Distribution by Year of Establishment
Figure 6.2 Small Molecules Fill / Finish Service Providers: Distribution by Company Size
Figure 6.3 Small Molecules Fill / Finish Service Providers: Distribution by Location of Headquarters
Figure 6.4 Small Molecules Fill / Finish Service Providers: Distribution by Location of Fill / Finish Facilities
Figure 6.5 Small Molecules Fill / Finish Service Providers: Distribution by Type of Filling Service(s) Offered
Figure 6.6 Small Molecules Fill / Finish Service Providers: Distribution by Type of Finishing Service(s) Offered
Figure 6.7 Small Molecules Fill / Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Figure 6.8 Small Molecules Fill / Finish Service Providers: Distribution by Scale of Operation
Figure 6.9 Small Molecules Fill / Finish Service Providers: Distribution by Type of Dosage Form(s) Filled
Figure 6.10 Small Molecules Fill / Finish Service Providers: Distribution by Type of Process(es)
Figure 7.1 AbbVie: Annual Revenues, 2017-H1 2022 (USD Billion)
Figure 7.2 Baxter (a parent company of BioPharma Solutions): Annual Revenues, 2017-H1 2022 (USD Billion)
Figure 7.3 Merck (a parent company of BioReliance): Annual Revenues, 2017-H1 2022 (EUR Billion)
Figure 7.4 Catalent Biologics: Annual Revenues, FY 2017-FY 2022 (USD Billion)
Figure 7.5 Charles River Laboratories: Annual Revenues, 2017-H1 2022 (USD Billion)
Figure 7.6 Thermo Fisher Scientific (a parent company of Patheon): Annual Revenues, 2017-H1 2022 (USD Billion)
Figure 7.7 Pfizer CentreOne: Annual Revenues, 2017-9M 2022 (USD Million)
Figure 8.1 Boehringer Ingelheim (a parent company of Boehringer Ingelheim BioXcellence): Annual Revenues, 2017-H1 2022 (EUR Billion)
Figure 8.2 GlaxoSmithKline: Annual Revenues, 2017 -H1 2022 (GBP Billion)
Figure 8.3 Lonza: Annual Revenues, 2017-H1 2022 (CHF Billion)
Figure 8.4 Pierre Fabre: Annual Revenues, 2018- 2021 (EUR Billion)
Figure 8.5 Wacker Chemie ( a parent company of Wacker Biotech): Annual Revenues, 2017-H1 2022 (EUR Billion)
Figure 8.6 Aenova: Annual Revenues, 2018-2021 (EUR Million)
Figure 8.7 Fresenius Kabi: Annual Revenues, 2017-9M 2022 (EUR Billion)
Figure 8.8 Recipharm: Annual Revenues, 2017- 2020 (SEK Billion)
Figure 8.9 Recipharm: Revenues by Business Divisions, 2020 (SEK Billion)
Figure 9.1 Asymchem: Annual Revenues, 2017-2020 (USD Billion)
Figure 9.2 Samsung Biologics: Annual Revenues, 2017-H1 2022 (KRW Billion)
Figure 9.3 Syngene: Annual Revenues, FY 2017-FY 2022 (INR Million)
Figure 9.4 Takara Bio: Annual Revenues, FY 2017-FY 2022 (JPY Billion)
Figure 9.5 WuXi Biologics: Annual Revenues, 2017-H1 2022 (RMB Million)
Figure 9.6 Siegfried: Annual Revenues, 2017-H1 2022 (CHF Million)
Figure 9.7 Wockhardt: Annual Revenues, FY 2017- FY Q1 2023 (INR Billion)
Figure 10.1 Partnerships and Collaborations: Cumulative Year wise Trend, 2013-2022
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 10.4 Partnerships and Collaborations: Distribution by Type of Molecule(s) Involved
Figure 10.5 Partnerships and Collaborations: Distribution by Type of Service(s) Offered
Figure 10.6 Partnerships and Collaborations: Distribution by Type of Process(es) Involved
Figure 10.7 Partnerships and Collaborations: Distribution by Type of Drug Product(s) Involved
Figure 10.8 Most Active Players: Distribution by Number of Partnerships
Figure 10.9 Partnerships and Collaborations: Distribution by Geography
Figure 10.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 11.1 Global Aseptic Fill / Finish Services Market, 2023-2035 (USD Billion)
Figure 11.2 Aseptic Fill / Finish Services Market: Distribution by Type of Molecule, 2023-2035 (USD Billion)
Figure 11.3 Aseptic Fill / Finish Services Market: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Figure 11.4 Aseptic Fill / Finish Services Market: Distribution by Type of Drug Product, 2023-2035 (USD Billion)
Figure 11.5 Aseptic Fill / Finish Services Market: Distribution by Target Therapeutic Area, 2023-2035 (USD Billion)
Figure 11.6 Aseptic Fill / Finish Services Market: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Figure 11.7 Aseptic Fill / Finish Services Market: Distribution by Company Size, 2023-2035 (USD Billion)
Figure 11.8 Aseptic Fill / Finish Services Market: Distribution by Geography, 2023-2035 (USD Billion)
Figure 11.9 Aseptic Fill / Finish Services Market for Biologics, 2023-2035 (USD Billion)
Figure 11.10 Aseptic Fill / Finish Services Market for Biologics: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Figure 11.11 Aseptic Fill / Finish Services Market for Biologics: Distribution by Type of Drug Product, 2023-2035 (USD Billion)
Figure 11.12 Aseptic Fill / Finish Services Market for Biologics: Distribution by Target Therapeutic Area, 2023-2035 (USD Billion)
Figure 11.13 Aseptic Fill / Finish Services Market for Biologics: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Figure 11.14 Aseptic Fill / Finish Services Market for Biologics: Distribution by Company Size, 2023-2035 (USD Billion)
Figure 11.15 Aseptic Fill / Finish Services Market for Biologics: Distribution by Geography, 2023-2035 (USD Billion)
Figure 11.16 Aseptic Fill / Finish Services Market for Small Molecules, 2023-2035 (USD Billion)
Figure 11.17 Aseptic Fill / Finish Services Market for Small Molecules: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Figure 11.18 Aseptic Fill / Finish Services Market for Small Molecules: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Figure 11.19 Aseptic Fill / Finish Services Market for Small Molecules: Distribution by Company Size, 2023-2035 (USD Billion)
Figure 11.20 Aseptic Fill / Finish Services Market for Small Molecules: Distribution by Geography, 2023-2035 (USD Billion)
Figure 12.1 Key Considerations for Selecting a Robotic System
Figure 12.2 Advantages of Robotic Systems in Pharmaceutical Operations
Figure 13.1 Key Drivers of Ready-to-Use Platform
Figure 14.1 Concluding Remarks: Current Biologic Fill / Finish Service Providers Market Landscape
Figure 14.2 Concluding Remarks: Current Small Molecule Fill / Finish Service Providers Market Landscape
Figure 14.3 Concluding Remarks: Partnerships and Collaborations
Figure 14.4 Concluding Remarks: Market Sizing and Opportunity Analysis
List Of Tables
Table 4.1 Aseptic Fill / Finish Service Providers: List of Companies
Table 4.2 Aseptic Fill / Finish Service Providers: Information on Type of Packaging Container(s) Offered
Table 5.1 Biologics Fill / Finish Service Providers: List of Companies
Table 5.2 Biologics Fill / Finish Service Providers: Information on Type of Packaging Container(s) Offered
Table 5.3 Biologics Fill / Finish Service Providers: Information on Type of Drug Product(s) Involved
Table 5.4 Biologics Fill / Finish Service Providers: Information on Scale of Operation
Table 5.5 Biologics Fill / Finish Service Providers: Information on Additional Drug Product-related Services Offered
Table 5.6 Biologics Fill / Finish Service Providers: Information on Fill / Finish Capacity
Table 6.1 Small Molecules Fill / Finish Service Providers: List of Companies
Table 6.2 Small Molecules Fill / Finish Service Providers: Information on Fill / Finish Technique
Table 6.3 Small Molecules Fill / Finish Service Providers: Information on Type of Packaging Container(s) Offered
Table 6.4 Small Molecules Fill / Finish Service Providers: Information on Scale of Operation
Table 6.5 Small Molecules Fill / Finish Service Providers: Information on Type of Dosage Form(s) Filled and Type of Process(es)
Table 6.6 Small Molecules Fill / Finish Service Providers: Information on Fill / Finish Capacity
Table 7.1 Biologics Fill / Finish Service Providers: List of Companies Profiled
Table 7.2 AbbVie Contract Manufacturing: Company Snapshot
Table 7.3 AbbVie Contract Manufacturing: Service Portfolio
Table 7.4 AbbVie Contract Manufacturing: Fill / Finish Services
Table 7.5 AbbVie Contract Manufacturing: Sterile Manufacturing Facilities
Table 7.6 AbbVie Contract Manufacturing: Recent Developments and Future Outlook
Table 7.7 BioPharma Solutions: Company Snapshot
Table 7.8 BioPharma Solutions: Service Portfolio
Table 7.9 BioPharma Solutions: Fill / Finish Services
Table 7.10 BioPharma Solutions: Sterile Manufacturing Facilities
Table 7.11 BioPharma Solutions: Recent Developments and Future Outlook
Table 7.12 BioReliance: Company Snapshot
Table 7.13 BioReliance: Service Portfolio
Table 7.14 BioReliance: Fill / Finish Services
Table 7.15 BioReliance: Sterile Manufacturing Facilities
Table 7.16 BioReliance: Recent Developments and Future Outlook
Table 7.17 Catalent Biologics: Company Snapshot
Table 7.18 Catalent Biologics: Service Portfolio
Table 7.19 Catalent Biologics: Fill / Finish Services
Table 7.20 Catalent Biologics: Sterile Manufacturing Facilities
Table 7.21 Catalent Biologics: Recent Developments and Future Outlook
Table 7.22 Charles River Laboratories: Company Snapshot
Table 7.23 Charles River Laboratories: Fill / Finish Services
Table 7.24 Charles River Laboratories: Sterile Manufacturing Facilities
Table 7.25 Charles River Laboratories: Recent Developments and Future Outlook
Table 7.26 Patheon: Company Snapshot
Table 7.27 Patheon: Service Portfolio
Table 7.28 Patheon: Fill / Finish Services
Table 7.29 Patheon: Recent Developments and Future Outlook
Table 7.30 Small Molecules Fill / Finish Service Providers: List of Companies Profiled
Table 7.31 Pfizer CentreOne: Company Snapshot
Table 7.32 Pfizer CentreOne: Service Portfolio
Table 7.33 Pfizer CentreOne: Fill / Finish Services
Table 7.34 Pfizer CentreOne: Recent Developments and Future Outlook
Table 7.35 Plastikon Healthcare: Company Snapshot
Table 7.36 Plastikon Healthcare: Service Portfolio
Table 7.37 Plastikon Healthcare: Fill / Finish Services
Table 7.38 Sharp Services: Company Snapshot
Table 7.39 Sharp Services: Service Portfolio
Table 7.40 Sharp Services: Fill / Finish Services
Table 7.41 Sharp Services: Recent Developments and Future Outlook
Table 8.1 Biologics Fill / Finish Service Providers in Europe: List of Companies Profiled
Table 8.2 Boehringer Ingelheim BioXcellence: Company Snapshot
Table 8.3 Boehringer Ingelheim BioXcellence: Service Portfolio
Table 8.4 Boehringer Ingelheim BioXcellence: Fill / Finish Services
Table 8.5 Boehringer Ingelheim BioXcellence: Sterile Manufacturing Facilities
Table 8.6 Boehringer Ingelheim BioXcellence: Recent Developments and Future Outlook
Table 8.7 Fareva: Company Snapshot
Table 8.8 Fareva: Fill / Finish Services
Table 8.9 Fareva: Recent Developments and Future Outlook
Table 8.10 Glaxo SmithKline: Company Snapshot
Table 8.11 Glaxo SmithKline: Fill / Finish Services
Table 8.12 Glaxo SmithKline: Recent Developments and Future Outlook
Table 8.13 Lonza: Company Snapshot
Table 8.14 Lonza: Service Portfolio
Table 8.15 Lonza: Fill / Finish Services
Table 8.16 Lonza: Recent Developments and Future Outlook
Table 8.17 Pierre Fabre: Company Snapshot
Table 8.18 Pierre Fabre: Service Portfolio
Table 8.19 Pierre Fabre: Fill / Finish Services
Table 8.20 Pierre Fabre: Sterile Manufacturing Facilities
Table 8.21 Pierre Fabre: Recent Developments and Future Outlook
Table 8.22 Wacker Biotech: Company Snapshot
Table 8.23 Wacker Biotech: Service Portfolio
Table 8.24 Wacker Biotech: Fill / Finish Services
Table 8.25 Wacker Biotech: Sterile Manufacturing Facilities
Table 8.26 Wacker Biotech: Recent Developments and Future Outlook
Table 8.27 Small Molecules Fill / Finish Service Providers in Europe: List of Companies Profiled
Table 8.28 Aenova: Company Snapshot
Table 8.29 Aenova: Service Portfolio
Table 8.30 Aenova: Fill / Finish Services
Table 8.31 Aenova: Recent Developments and Future Outlook
Table 8.32 APL: Company Snapshot
Table 8.33 APL: Service Portfolio
Table 8.34 APL: Fill / Finish Services
Table 8.35 CordenPharma: Company Snapshot
Table 8.36 CordenPharma: Service Portfolio
Table 8.37 CordenPharma: Fill / Finish Services
Table 8.38 CordenPharma: Recent Developments and Future Outlook
Table 8.39 Delpharm: Company Snapshot
Table 8.40 Delpharm: Service Portfolio
Table 8.41 Delpharm: Fill / Finish Services
Table 8.42 Delpharm: Recent Developments and Future Outlook
Table 8.43 PiSA Farmaceutica: Company Snapshot
Table 8.44 PiSA Farmaceutica: Fill / Finish Services
Table 8.45 Biologics and Small Molecules Fill / Finish Service Providers in Europe: List of Companies Profiled
Table 8.46 Fresenius Kabi: Company Snapshot
Table 8.47 Fresenius Kabi: Fill / Finish Services
Table 8.48 Recipharm: Company Snapshot
Table 8.49 Recipharm: Service Portfolio
Table 8.50 Recipharm: Fill / Finish Services
Table 8.51 Recipharm: Recent Developments and Future Outlook
Table 9.1 Biologics Fill / Finish Service Providers in Asia-Pacific: List of Companies Profiled
Table 9.2 Asymchem: Company Snapshot
Table 9.3 Asymchem: Service Portfolio
Table 9.4 Asymchem: Fill / Finish Services
Table 9.5 Asymchem: Sterile Manufacturing Facilities
Table 9.6 Asymchem: Recent Developments and Future Outlook
Table 9.7 Samsung Biologics: Company Snapshot
Table 9.8 Samsung Biologics: Service Portfolio
Table 9.9 Samsung Biologics: Fill / Finish Services
Table 9.10 Samsung Biologics: Recent Developments and Future Outlook
Table 9.11 Syngene: Company Snapshot
Table 9.12 Syngene: Service Portfolio
Table 9.13 Syngene: Fill / Finish Services
Table 9.14 Syngene: Recent Developments and Future Outlook
Table 9.15 Takara Bio: Company Snapshot
Table 9.16 Takara Bio: Service Portfolio
Table 9.17 Takara Bio: Fill / Finish Services
Table 9.18 Takara Bio: Recent Developments and Future Outlook
Table 9.19 WuXi Biologics: Company Snapshot
Table 9.20 WuXi Biologics: Services Portfolio
Table 9.21 Wuxi Biologics: Fill / Finish Services
Table 9.22 WuXi Biologics: Sterile Manufacturing Facilities
Table 9.23 WuXi Biologics: Recent Developments and Future Outlook
Table 9.24 Hetero Drugs: Company Snapshot
Table 9.25 Hetero Drugs: Fill / Finish Services
Table 9.26 Intas Pharmaceuticals: Company Snapshot
Table 9.27 Intas Pharmaceuticals: Fill / Finish Services
Table 9.28 Small Molecules Fill / Finish Service Providers in Asia-Pacific: List of Companies Profiled
Table 9.29 Siegfried: Company Snapshot
Table 9.30 Siegfried: Service Portfolio
Table 9.31 Siegfried: Fill / Finish Services
Table 9.32 Siegfried: Recent Developments and Future Outlook
Table 9.33 Wockhardt: Company Snapshot
Table 9.34 Wockhardt: Fill / Finish Services
Table 9.35 Wockhardt: Recent Developments and Future Outlook
Table 10.1 Aseptic Fill / Finish Service Providers: Partnerships and Collaborations
Table 10.2 Partnerships and Collaborations: Information on Type of Molecule(s) Involved and Type of Service(s) Offered
Table 10.3 Partnerships and Collaborations: Information on Type of Drug Product(s) Involved and Type of Process(es) Involved
Table 12.1 Contract Service Providers: Information on Fill / Finish Equipment
Table 12.2 List of Pharmaceutical Robotics Manufacturers
Table 12.3 Isolator based Aseptic Filling Systems: Information on Compatible Primary Container
Table 13.1 List of Companies Supplying Ready-to-Use Aseptic Packaging Components
Table 16.1 Aseptic Fill / Finish Service Providers: Distribution by Year of Establishment
Table 16.2 Aseptic Fill / Finish Service Providers: Distribution by Company Size
Table 16.3 Aseptic Fill / Finish Service Providers: Distribution by Location of Headquarters
Table 16.4 Aseptic Fill / Finish Service Providers: Distribution by Type of Molecule(s)
Table 16.5 Aseptic Fill / Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Table 16.6 Biologics Fill / Finish Service Providers: Distribution by Year of Establishment
Table 16.7 Biologics Fill / Finish Service Providers: Distribution by Company Size
Table 16.8 Biologics Fill / Finish Service Providers: Distribution by Location of Headquarters
Table 16.9 Biologics Fill / Finish Service Providers: Distribution by Location of Fill / Finish Facilities
Table 16.10 Biologics Fill / Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Table 16.11 Biologics Fill / Finish Service Providers: Distribution by Type of Packaging Container(s) Offered and Type of Drug Product(s) Involved
Table 16.12 Biologics Fill / Finish Service Providers: Distribution by Scale of Operation
Table 16.13 Biologics Fill / Finish Service Providers: Distribution by Additional Drug Product-related Services Offered
Table 16.14 Small Molecules Fill / Finish Service Providers: Distribution by Year of Establishment
Table 16.15 Small Molecules Fill / Finish Service Providers: Distribution by Company Size
Table 16.16 Small Molecules Fill / Finish Service Providers: Distribution by Location of Headquarters
Table 16.17 Small Molecules Fill / Finish Service Providers: Distribution by Location of Fill / Finish Facilities
Table 16.18 Small Molecules Fill / Finish Service Providers: Distribution by Type of Filling Service(s) Offered
Table 16.19 Small Molecules Fill / Finish Service Providers: Distribution by Type of Finishing Service(s) Offered
Table 16.19 Small Molecules Fill / Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Table 16.20 Small Molecules Fill / Finish Service Providers: Distribution by Scale of Operation
Table 16.21 Small Molecules Fill / Finish Service Providers: Distribution by Type of Dosage Form(s) Filled
Table 16.22 Small Molecules Fill / Finish Service Providers: Distribution by Type of Process(es)
Table 16.23 AbbVie: Annual Revenues, 2017-H1 2022 (USD Billion)
Table 16.24 Baxter (a parent company of BioPharma Solutions): Annual Revenues, 2017-H1 2022 (USD Billion)
Table 16.25 Merck (a parent company of BioReliance): Annual Revenues, 2017-H1 2022 (EUR Billion)
Table 16.26 Catalent Biologics: Annual Revenues, FY 2017-FY 2022 (USD Billion)
Table 16.27 Charles River Laboratories: Annual Revenues, 2017-H1 2022 (USD Billion)
Table 16.28 Thermo Fisher Scientific (a parent company of Patheon): Annual Revenues, 2017-H1 2022 (USD Billion)
Table 16.29 Pfizer CentreOne: Annual Revenues, 2017-9M 2022 (USD Million)
Table 16.30 Boehringer Ingelheim (a parent company of Boehringer Ingelheim BioXcellence): Annual Revenues, 2017-H1 2022 (EUR Billion)
Table 16.31 GlaxoSmithKline: Annual Revenues, 2017 -H1 2022 (GBP Billion)
Table 16.32 Lonza: Annual Revenues, 2017-H1 2022 (CHF Billion)
Table 16.33 Pierre Fabre: Annual Revenues, 2018- 2021 (EUR Billion)
Table 16.34 Wacker Chemie ( a parent company of Wacker Biotech): Annual Revenues, 2017-H1 2022 (EUR Billion)
Table 16.35 Aenova: Annual Revenues, 2018-2021 (EUR Million)
Table 16.36 Fresenius Kabi: Annual Revenues, 2017-9M 2022 (EUR Billion)
Table 16.37 Recipharm: Annual Revenues, 2017- 2020 (SEK Billion)
Table 16.38 Recipharm: Revenues by Business Divisions, 2020 (SEK Billion)
Table 16.39 Asymchem: Annual Revenues, 2017-2020 (USD Billion)
Table 16.40 Samsung Biologics: Annual Revenues, 2017-H1 2022 (KRW Billion)
Table 16.41 Syngene: Annual Revenues, FY 2017-FY 2022 (INR Million)
Table 16.42 Takara Bio: Annual Revenues, FY 2017-FY 2022 (JPY Billion)
Table 16.43 WuXi Biologics: Annual Revenues, 2017-H1 2022 (RMB Million)
Table 16.44 Siegfried: Annual Revenues, 2017-H1 2022 (CHF Million)
Table 16.45 Wockhardt: Annual Revenues, FY 2017- FY Q1 2023 (INR Billion)
Table 16.46 Partnerships and Collaborations: Cumulative Year wise Trend, 2013-2022
Table 16.47 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.48 Partnerships and Collaborations: Distribution by Scale of Operation
Table 16.49 Partnerships and Collaborations: Distribution by Type of Molecule(s) Involved
Table 16.50 Partnerships and Collaborations: Distribution by Type of Service(s) Offered
Table 16.51 Partnerships and Collaborations: Distribution by Type of Process(es) Involved
Table 16.52 Partnerships and Collaborations: Distribution by Type of Drug Product(s) Involved
Table 16.53 Most Active Players: Distribution by Number of Partnerships
Table 16.54 Partnerships and Collaborations: Distribution by Geography
Table 16.55 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 16.56 Global Aseptic Fill / Finish Services Market, 2023-2035 (USD Billion)
Table 16.57 Aseptic Fill / Finish Services Market, Conservative, Base and Optimistic Scenarios: Distribution by Type of Molecule, 2023-2035 (USD Billion)
Table 16.58 Aseptic Fill / Finish Services Market, Conservative, Base and Optimistic Scenarios: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Table 16.59 Aseptic Fill / Finish Services Market, Conservative, Base and Optimistic Scenarios: Distribution by Type of Drug Product, 2023-2035 (USD Billion)
Table 16.60 Aseptic Fill / Finish Services Market, Conservative, Base and Optimistic Scenarios: Distribution by Target Therapeutic Area, 2023-2035 (USD Billion)
Table 16.61 Aseptic Fill / Finish Services Market, Conservative, Base and Optimistic Scenarios: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Table 16.62 Aseptic Fill / Finish Services Market, Conservative, Base and Optimistic Scenarios: Distribution by Company Size, 2023-2035 (USD Billion)
Table 16.63 Aseptic Fill / Finish Services Market, Conservative, Base and Optimistic Scenarios: Distribution by Geography, 2023-2035 (USD Billion)
Table 16.64 Aseptic Fill / Finish Services Market for Biologics, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 16.65 Aseptic Fill / Finish Services Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Table 16.66 Aseptic Fill / Finish Services Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Type of Drug Product, 2023-2035 (USD Billion)
Table 16.67 Aseptic Fill / Finish Services Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Target Therapeutic Area, 2023-2035 (USD Billion)
Table 16.68 Aseptic Fill / Finish Services Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Table 16.69 Aseptic Fill / Finish Services Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Company Size, 2023-2035 (USD Billion)
Table 16.70 Aseptic Fill / Finish Services Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Geography, 2023-2035 (USD Billion)
Table 16.71 Aseptic Fill / Finish Services Market for Small Molecules, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 16.72 Aseptic Fill / Finish Services Market for Small Molecules, Conservative, Base and Optimistic Scenarios: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Table 16.73 Aseptic Fill / Finish Services Market for Small Molecules, Conservative, Base and Optimistic Scenarios: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Table 16.74 Aseptic Fill / Finish Services Market for Small Molecules, Conservative, Base and Optimistic Scenarios: Distribution by Company Size, 2023-2035 (USD Billion)
Table 16.75 Aseptic Fill / Finish Services Market for Small Molecules, Conservative, Base and Optimistic Scenarios: Distribution by Geography, 2023-2035 (USD Billion)
Companies Mentioned
- 3P Biopharmaceuticals
- Aalto Scientific
- ABB
- AbbVie
- AbbVie Contract Manufacturing
- AbTis
- Abzena
- ACG
- ACIC Pharmaceutical Machinery
- AdaptVac
- ADC Biotechnology
- Adimmune
- Advanced BioScience Laboratories
- Aenova
- Affinity Life Sciences
- Afton Scientific
- Agilis Biotherapeutics
- AJ Biologics
- Ajinomoto Bio-Pharma
- Akorn
- Akron Biotech
- Akso Biopharmaceutical
- Akums Drugs & Pharmaceuticals
- Alanza
- Alcami (Acquired by GHO Capital and The Vistria Group)
- Alcon
- Aldevron
- Alkermes
- Allergy Laboratories
- Althea
- Amatsigroup
- Ambica Pharma Machines
- Amgen
- Amicus Therapeutics
- Amsino International
- Anchiano Therapeutics (formerly known as BioCanCell)
- Anchor Mark
- Anthos Therapeutics
- apceth Biopharma
- APG Europe
- ApiJect Systems
- APL
- Aptar Pharma
- Aptuit
- Arabio
- ARaymond Life
- Arch Biopartners
- Argonaut Manufacturing Services
- ARISTO Pharmaceuticals
- Ascendia Pharmaceuticals
- Asept Pak
- Aseptic Technologies
- Asklepios BioPharmaceutical
- AST
- AstraZeneca
- Asymchem
- Ausia Biotech
- Austrianova
- Automated Systems of Tacoma
- Avara Pharmaceutical Services
- Avid Bioservices
- Avrio Biopharmaceuticals
- AWS Bio-Pharma Technologies
- Axcellerate Pharma
- B. Braun’s OEM Division
- Baccinex
- Basic Pharma
- Bausch & Ströbel
- BAUSCH Advanced Technology (BATG)
- Baxter BioPharma Solutions
- Bayer
- BD
- BePharBel Manufacturing
- Berkshire Sterile Manufacturing
- Binex
- Bio Elpida
- Bio-Concept Laboratories
- BioConnection
- Biofabri
- Biogen
- BioMARC
- Biomay
- Biomedical Advanced Research and Development Authority (BARDA)
- BioNTech
- BioPharma Solutions
- BioReliance
- Bio-Serv
- BioSkryb Genomics
- BioTechLogic
- BioTechnique
- Biovian
- BirgiMefar
- Boehringer Ingelheim BioXcellence
- Bolt Biotherapeutics
- Bosch Packaging Technology
- Boston Children’s Hospital
- Bristol-Myers Squibb
- Bryllan
- BSP Pharmaceuticals
- Burrard Pharmaceuticals
- Bushu Pharmaceuticals
- Cangene Corporation (Acquired by Emergent BioSolutions)
- Canton Biologics
- Capmatic
- CARBOGEN AMCIS
- Carlyle
- Catalent Biologics
- Catalent Pharma Solutions
- Celgene
- Cell Culture Company
- Cellin Technologies
- Celonic
- Celsee
- Cenexi
- Cerbios-Pharma
- Cerium Pharmaceuticals
- Chase-Logeman
- Chemigran
- ChemPartner
- Chime Biologics
- China Gateway Biologics
- CinnaGen
- Cirondrugs
- Citryll
- CMAB Biopharma
- CMC Biologics
- CMIC CMO
- Coalition for the Promotion of Innovations for Epidemic Preparedness (CEPI)
- Cobra Biologics
- C.O.C. Farmaceutici
- Cognate BioServices
- Cognitus Consulting
- Coldstream Laboratories
- Colorado State University
- Columbus Venture Partners
- Comecer
- Concord Drugs
- Cook Pharmica
- CordenPharma
- Cozzoli Machine Company
- Creative Biolabs
- CreoSalus
- Crystal Pharma
- CureVac
- Curida
- CytoDyn
- Cytovance Biologics
- Daikyo Seiko
- Dalton Pharma Services
- Dara Pharma
- Datwyler Sealing Solutions
- Delpharm
- DENSO
- Dhruv Life Sciences
- Disposable Lab
- DM Bio
- Drugs for Neglected Disease Initiative (DNDi)
- DSM Pharmaceutical Products
- DWK Life Sciences
- EirGen Pharma
- EirGenix
- Eli Lilly
- EMA Pharmaceuticals
- EMCM
- Emcure Pharmaceuticals
- Emergent BioSolutions
- Esco Aster
- Etinpro
- EuBiologics
- EUCODIS Bioscience
- Eurofins
- Eurofins BioPharma Product Testing Netherlands (EBPT NL)
- Euro-Med Laboratories
- EVER Pharma
- Evonik Health Care
- ExCellThera
- Exelead
- Experic
- Extract Technology
- FANUC America
- Fareva
- FinVector
- Flamingo Pharmaceuticals
- Formosa Laboratories
- Fresenius Kabi Contract Manufacturing
- Früh Verpackungstechnik
- FUJIFILM Diosynth Biotechnologies
- GC Pharma
- GEA
- Gebro Pharma
- Genentech
- GeneQuantum Healthcare
- Generic Specialities
- GenIbet Biopharmaceuticals
- Genovior Biotech
- Genprex
- Gerresheimer
- Getinge
- GigaGen
- Gilead
- Gland Pharma
- GLyPharma
- Goodwin Biotechnology
- GP Pharm
- Grand River Aseptic Manufacturing
- groninger
- GSK
- GTCR
- Gulf Biotech
- HALIX
- hameln pharma
- Handl Therapeutics
- Hanford Pharmaceuticals
- Hansa Biopharma
- Hapten Sciences
- Health Biotech
- Healthcare Pharmaceuticals
- Healthy Life Pharma
- Hepalink
- Hetero Drugs
- Hisun Pharmaceuticals USA
- HOOKIPA Pharma
- Horizon Therapeutics
- Hospira (Acquired by Pfizer)
- Humanigen
- Hybio Pharmaceutical
- Hycult Biotech
- iBio
- IDT Australia
- IDT Biologika
- IMA Group
- Immune Pharmaceuticals
- Immunex
- INCOG BioPharma Services
- Indicia
- Industria Macchine Automatiche (IMA)
- Infectious Disease Research Institute
- Injectalia (A subsidiary of Orofino Pharmaceuticals)
- Intas Pharmaceuticals
- Integrity Bio
- Irvine Pharmaceutical Services
- Istituto Biochimico Italiano Giovanni Lorenzini
- Janssen Pharmaceuticals
- JHL Biotech
- Jiangsu Yaohai Bio-pharmaceutical
- Johnson & Johnson
- JOINN Biologics
- Jubilant HollisterStier
- Kanda BioTech
- Kaneka Eurogentec
- Kawasaki Heavy Industries
- Kaysersberg Pharmaceuticals (Acquired by Recipharm)
- Kemwell Biopharma
- Klenzaids
- Kohlberg and Mubadala
- KP Pharmaceutical Technology
- KUKA
- Kymanox
- Laboratorios Farmaceuticos ROVI
- Laekna Therapeutics
- LakePharma
- LamKap Bio
- Lava Therapeutics
- Legacy Pharmaceuticals
- LESVI
- Lifecore Biomedical
- Liof Pharma
- Lohmann Pharma Herstellung
- Lomapharm
- Lonza
- Lubrizol
- LuinaBio
- LyoGen
- Lyophilization Services of New England (LSNE) (Acquired by PCI Pharma)
- Lyophilization Technology
- M&O Perry
- MabPlex
- MabPlex
- Madison Dearborn Partners
- Magle Chemoswed
- Makcur Laboratories
- Marchesini Group
- MassBiologics
- Massman Automation Designs
- MaSTherCell
- Masy BioServices
- MEDInstill
- Merck
- Microdermics
- Millmount Healthcare (Acquired by PCI Pharma Services)
- Miltenyi Biotec
- Minaris Regenerative Medicine
- Mithra CDMO
- Mitsubishi Electric
- Moderna
- Morgridge Institute for Research (MIR)
- Mycenax Biotech
- Najít Technologies
- National Health Research Institutes (NHRI)
- National Institutes of Health
- Navesta
- NBE Therapeutics
- Nephron Pharmaceuticals
- Neuma (Acquired by Kymanox)
- New Vision Pharmaceuticals
- NextPharma
- Nikon CeLL innovation
- Ningbo Zhengli Pharmaceutical Packing
- Nipro PharmaPackaging
- Nitto Avecia
- n-Lorem Foundation
- Northway Biotech
- Nova Laboratories
- Novartis
- Novasep
- Novavax
- Noveome Biotherapeutics
- Novex Innovations
- Novo Nordisk
- Novocol Pharma
- Nykode Therapeutics (formerly known as Vaccibody)
- Oakwood Labs
- Ology Bioservices
- OmniChem
- OMRON Industrial Automation
- oncomed manufacturing
- Oncotec Pharma Produktion
- OPKO Health
- OPTIMA
- Ori Biotech
- Orion Corporation
- Oryn Therapeutics
- OSO Biopharmaceuticals Manufacturing (Acquired by AMRI)
- Ottawa Hospital Research Institute
- Oxford BioMedica
- Pace Analytical
- PaizaBio
- Pall Life Sciences
- Panacea Pharmaceuticals
- Panpharma
- Paragon Bioservices
- Particle Measuring Systems (PMS)
- Partners Group
- Patheon (Acquired by Thermo Fisher Scientific)
- PCI Pharma Services
- Penn Pharmaceutical Services
- Permira
- Pfizer
- Pfizer CentreOne
- Pharma Stulln
- Pharmaceutical Packaging Professionals
- Pharmaceutics International
- Pharma-Q
- Pharmaster
- PharmaTher
- Pierre Fabre
- Pii (Pharmaceutics International Inc.)
- Piramal Pharma Solutions
- PiSA Farmacéutica
- Plastikon Healthcare
- PMI BioPharma Solutions
- Polfa Tarchomin
- Polpharma Biologics
- Polymun Scientific
- Praxis Pharmaceutical
- PrimaPharma
- Prince Sterilization Services
- PSC Biotech
- PYRAMID Laboratories
- Quality BioResources
- QureBio
- Recipharm
- Regeneron Pharmaceuticals
- Reliance Life Sciences
- Renaissance Lakewood
- Rentschler Biopharma
- Rentschler Fill Solutions
- Resilience
- Revance Therapeutics
- Roche
- Romaco
- Rommelag CMO
- Rompharm
- RoslinCT
- ROTA Verpackungstechnik
- Ruibo Bio-Technology
- Russian Direct Investment Fund (RDIF)
- Saint-Gobain
- Salvat
- Sam Chun Dang Pharm
- Samsung Bioepis
- Samsung Biologics
- Sandoz
- Sanofi
- Saudi Biotechnology Manufacturing
- Schematic Engineering Industries
- SCHOTT
- ScinoPharm
- Seiko Epson
- Selecta Biosciences
- Selkirk Pharma
- Sensorion
- Sentiss Pharma
- BravoBio
- Sharp
- Shengnuo Peptide
- Shenzhen Techdow Pharmaceutical
- Sherpa Clinical Packaging (Acquired by PCI Pharma Services)
- Shibuya
- Shree Bhagwati Machtech
- SialoCarb
- Siam Bioscience
- Siegfried Holding
- Singota Solutions
- Sio Gene Therapies
- SiO2 Medical Products
- SIRION Biotech
- Sirton Pharmaceuticals
- SKAN
- Snowbell Machines
- Societal CDMO
- SP Industries
- Spanish Agency of Medicines and Medical Devices (AEMPS)
- Square Pharmaceuticals
- Staubli
- Stelis Biopharma
- Steriline
- Stevanato
- Surrozen
- Swissfillon
- Symbiosis Pharmaceutical
- Symphogen
- SynCo Bio Partners
- Syngene
- Synklino
- Syntegon
- Sypharma
- TAIYO Pharma
- Takara Bio
- Tanvex BioPharma
- Taysha Gene Therapies
- Tekpak
- ten23 health
- Themis Medicare
- Therapure Biomanufacturing
- Theratechnologies
- Thermo Fisher Scientific
- Tofflon
- Transcoject
- TransMedics
- TriPharm Services (Acquired by Alcami)
- Truking Technology
- Tubulis
- U.S. Army Contracting Command (ACC)
- UCB
- Ultragenyx Pharmaceutical
- Unicep
- Unipharma
- Unither Pharmaceuticals
- Universal Robots
- University of Iowa Pharmaceuticals
- University of Queensland
- Unolab Manufacturing
- USV
- Vaccine and Infectious Disease Organization (VIDO)
- Vanrx Pharmasystems
- Vaxine
- VBI Vaccines
- Vetter Pharma
- VGXI
- Vibalogics
- Vigene Biosciences
- Viralgen
- V-nano
- VxP Biologics
- VxP Pharma
- WACKER Biotech
- Waisman Biomanufacturing
- Watson-Marlow
- West Pharmaceutical Services
- Wockhardt
- WuXi Biologics
- Wuxi Fortune Pharmaceutical
- Wuxi Griffin
- Yaskawa Electric
- Yposkesi
- Zoetis
Methodology
LOADING...
